Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen:Novel viral biomarkers for chronic hepatitis B management  

作　　者：Wattana Leowattana Pathomthep Leowattana Tawithep Leowattana 

机构地区：[1]Department of Clinical Tropical Medicine,Mahidol University,Rachatawee 10400,Bangkok,Thailand [2]Department of Medicine,Srinakharinwirot University,Wattana 10110,Bangkok,Thailand

出　　处：《World Journal of Hepatology》2024年第4期550-565,共16页世界肝病学杂志（英文版）（电子版）

摘　　要：The management of hepatitis B virus(HBV)infection now involves regular and appropriate monitoring of viral activity,disease progression,and treatment response.Traditional HBV infection biomarkers are limited in their ability to predict clinical outcomes or therapeutic effectiveness.Quantitation of HBV core antibodies(qAnti-HBc)is a novel non-invasive biomarker that may help with a variety of diagnostic issues.It was shown to correlate strongly with infection stages,hepatic inflammation and fibrosis,chronic infection exacerbations,and the presence of occult infection.Furthermore,qAnti-HBc levels were shown to be predictive of spontaneous or treatment-induced HBeAg and HBsAg seroclearance,relapse after medication termination,re-infection following liver transplantation,and viral reactivation in the presence of immunosuppression.qAnti-HBc,on the other hand,cannot be relied on as a single diagnostic test to address all problems,and its diagnostic and prognostic potential may be greatly increased when paired with qHBsAg.Commercial qAnti-HBc diagnostic kits are currently not widely available.Because many methodologies are only semi-quantitative,comparing data from various studies and defining universal cut-off values remains difficult.This review focuses on the clinical utility of qAnti-HBc and qHBsAg in chronic hepatitis B management.

关 键 词：Quantitative hepatitis B core antibody Quantitative hepatitis B surface antigen Chronic hepatitis B management Novels viral biomarkers 

分 类 号：R512.62[医药卫生—内科学]